Yaling Han
Northern Hospital
Internal medicineSurgeryCardiologyRandomized controlled trialClinical endpointDrug-eluting stentAspirinAcute coronary syndromeClopidogrelSirolimusCoronary artery diseaseStentAngioplastyPercutaneous coronary interventionMaceTarget lesionConventional PCIMyocardial infarctionMedicineBiologyGastroenterologyCell biology
399Publications
31H-index
4,073Citations
Publications 394
Newest
#1Birgit Vogel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 16
#2Usman Baber (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 44
Last. Roxana Mehran (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 162
view all 30 authors...
Importance Shortened dual antiplatelet therapy followed by potent P2Y12 receptor inhibitor monotherapy reduces bleeding without increasing ischemic events after percutaneous coronary intervention (PCI). Objective To explore sex differences and evaluate the association of sex with outcomes among patients treated with ticagrelor monotherapy vs ticagrelor plus aspirin. Design, Setting, and Participants This was a prespecified secondary analysis of TWILIGHT, an investigator-initiated, placebo-contro...
Source
Source
Source
OBJECTIVES To evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12 months on long-term prognosis in acute coronary syndrome (ACS) patients complicated with anemia undergoing percutaneous coronary intervention (PCI). BACKGROUND Anemia is frequent among ACS patients and is associated with increased risk of adverse clinical outcomes. METHODS A total of 6,953 patients were enrolled from the Optimal anti Platelet Therapy for Chinese patients with Coronary Artery Disease (OPT-CAD...
Source
#1Kai XuH-Index: 1
#1Kai Xu (Shenyang)
Last. Wenyue PangH-Index: 4
view all 13 authors...
AIMS: This analysis presents the final 5-year results of the I-LOVE-IT 2 trial, a noninferiority study comparing BP- sirolimus-eluting stent (SES) with DP-SES in patients with coronary artery disease. METHODS AND RESULTS: Overall, 2737 Chinese patients eligible for coronary stenting were treated with BP- or DP-SES in a 2:1 ratio. Patients who were randomized to BP-SES group were additionally re-randomized to receive either 6-month or 12-month dual antiplatelet therapy (DAPT) in a 1:1 ratio. The ...
Source
#1Juan Zhou (Xi'an Jiaotong University)H-Index: 13
#2Chee Tang ChinH-Index: 8
Last. Zuyi Yuan (Xi'an Jiaotong University)H-Index: 27
view all 14 authors...
Abstract Objectives To describe long-term antithrombotic management patterns (AMPs) in medically managed Asian patients with non-ST-segment myocardial infarction (NSTEMI) or unstable angina (UA). Background Current guidelines support an early invasive strategy in NSTEMI and UA patients, but many are medically managed, and data are limited on long-term AMPs in Asia. Methods Data were analyzed from medically managed NSTEMI and UA patients included in the prospective, observational EPICOR Asia stud...
Source
OBJECTIVE This study aimed at comparing the effectiveness and safety of ticagrelor and clopidogrel in acute coronary artery syndrome (ACS) patients stratified by the Optimal Antiplatelet Therapy for Chinese Patients with Coronary Artery Disease (OPT-CAD) risk score. BACKGROUND Although they provide a promising basis for treatment decisions, risk scores have not been utilized to optimize P2Y12 inhibitors for ACS patients. METHODS In 2016-2019, 16,343 ACS patients who underwent percutaneous corona...
Source
OBJECTIVES To explore the impact of 6- versus 12-month dual antiplatelet therapy (DAPT) on the clinical prognosis of high bleeding risk (HBR) patients. BACKGROUND The optimal DAPT duration after percutaneous coronary intervention (PCI) in HBR patients is unclear. METHODS This study is a post hoc analysis of the 4-year clinical follow-up results of the I LOVE IT 2 study. Prevalence and prognosis of HBR patients were explored, and clinical outcomes of HBR patients who underwent 6- versus 12-month ...
Source
#1Zhen GeH-Index: 12
#2Xiao-Fei GaoH-Index: 16
Last. Shao-Liang ChenH-Index: 38
view all 28 authors...
Abstract Background Current guidelines recommend administering dual antiplatelet therapy (DAPT) for 12 months to patients with acute coronary syndromes (ACS) and without contraindications after drug-eluting stent (DES) implantation. A recent study reported that 3 months of DAPT followed by ticagrelor monotherapy is effective and safe in ACS patients undergoing DES implantation compared with the standard duration of DAPT. However, it is unclear whether antiplatelet monotherapy with ticagrelor alo...
Source
#1Yong Huo (PKU: Peking University)H-Index: 35
#2Frans Van de Werf (Katholieke Universiteit Leuven)H-Index: 122
Last. Héctor BuenoH-Index: 79
view all 12 authors...
BACKGROUND Information is lacking on long-term management of patients with acute coronary syndrome (ACS) and chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2). OBJECTIVES Our objectives were to describe antithrombotic management patterns and outcomes in patients with ACS with varying renal function from the EPICOR (long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndrome patients; NCT01171404) and EPICOR Asia (NCT01361386) ...
Source